skip-to-main

Spikevax (previously COVID‑19 Vaccine Moderna)

A Conditional Marketing Authorisation (CMA) has been granted in the EU for the product Spikevax (previously COVID‑19 Vaccine Moderna) to prevent coronavirus disease 2019 (COVID‑19) in people from 6 years of age.

Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Contact Moderna

8am-5pm CET – Mon - Fri
EMEAMedinfo@modernatx.com